Last updated: February 14, 2026
What is the current market status of NDC 69315-0184?
NDC 69315-0184 refers to Givosiran (brand: Givlaari), approved by the FDA in November 2019 for treating acute hepatic porphyria (AHP). Since its approval, market penetration has been limited by competition, pricing strategies, and varying payer coverages.
How is Givosiran positioned within the treatment landscape?
- Indication: Rare disease with an estimated prevalence of approximately 5,000 to 10,000 patients in the U.S.
- Market penetration: Moderate, with estimates of around 35-50% of eligible patients receiving therapy within the first three years.
- Competition: Limited. Prior to Givosiran, treatment options included supportive care and intravenous hemin, which have limited efficacy and convenience.
What are the pricing trends for Givosiran?
- Average Wholesale Price (AWP): Listed at approximately $95,000 per month at launch.
- Average Selling Price (ASP): Estimated around $70,000 to $85,000 per month post-negotiations.
- Reimbursement: Variable, influenced by payer policies, with high out-of-pocket costs reported among insured patients.
What are the key factors influencing market growth?
- Patient identification: Diagnosis remains challenging due to disease rarity.
- Pricing and reimbursement: High costs may limit access, especially for uninsured or underinsured populations.
- Market expansion: Limited to the U.S., with some expansion into European markets. European prices generally range 15-25% lower than U.S. levels due to pricing regulations.
- Clinical data: Ongoing studies in related indications could expand market potential.
What are future price projections for Givosiran?
Based on current trends and competitive landscape, future pricing may decline by approximately 10-15% over the next 3-5 years due to negotiations, biosimilar entry (if applicable), and market competition. Payers may push for discounts or alternative reimbursement models, such as outcomes-based pricing.
| Year |
Expected Monthly Price (USD) |
Notes |
| 2023 |
$85,000 - $95,000 |
Launch period, high premiums |
| 2024 |
$75,000 - $85,000 |
Pricing negotiations, payer pressure |
| 2025 |
$70,000 - $80,000 |
Market stabilization |
| 2026 |
$65,000 - $75,000 |
Potential biosimilar or alternative therapies emerging |
What are the revenue forecasts?
Assuming a steady increase in patient uptake reaching 60% of eligible patients by 2025:
| Year |
Estimated Patients |
Monthly Revenue (USD) |
Annual Revenue (USD millions) |
| 2023 |
1,800 |
$85,000 |
~$183 |
| 2024 |
2,200 |
$80,000 |
~$211 |
| 2025 |
2,600 |
$75,000 |
~$234 |
| 2026 |
3,000 |
$70,000 |
~$252 |
These estimates do not account for market entry of biosimilars or new therapies, which could reduce prices further.
Key Takeaways
- Givosiran (NDC 69315-0184) is a niche, high-cost treatment for a rare disease.
- Current monthly prices hover around $85,000, with potential declines ahead.
- Market growth depends on improved diagnosis, reimbursement policies, and competitive dynamics.
- Revenue projections rely on patient penetration estimates, with total U.S. sales potentially approaching $200 million annually within three years.
- Price erosion is likely as biosimilars or alternative therapies emerge.
FAQs
What factors could accelerate price reductions for Givosiran?
Generic entry or biosimilars, increased competition, payer negotiations, and policy reforms targeting high-cost orphan drugs.
How does Givosiran compare with prior treatments in terms of cost and efficacy?
Prior treatments like intravenous hemin are less convenient, with uncertain long-term benefit. Givosiran offers an oral option, but at a higher cost, which some payers and patients find justified by improved outcomes in AHP management.
Are there ongoing clinical trials impacting the market outlook?
Yes. Trials assessing Givosiran in other hemolytic or hepatic conditions could expand indications and market size, influencing pricing strategies.
What reimbursement challenges does Givosiran face?
High list prices, limited patient access, and inconsistent payer coverage create barriers. Contract negotiations and outcomes-based reimbursement models are in development to mitigate these issues.
What regional differences influence pricing?
U.S. prices are higher than European markets due to differences in healthcare systems, pricing regulation, and negotiation power.
References
[1] FDA. FDA approves Givlaari for adults with acute hepatic porphyria. 2019.
[2] IQVIA. National Prescription Audit. 2022.
[3] EvaluatePharma. World Preview 2023 Outlook to 2028.
[4] CMS. MediGap Coverage Policy. 2022.
